RLMD vs SMMT
RLMD: Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | RLMD | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $5.20 | $14.98 | |
| Market cap as of 2026-07-25 | $543M | $10.6B | |
| PEG as of 2026-07-25 | n/a | -1.21 | |
| Net margin as of 2026-07-25 | -500.0% | -9027.1% | RLMD higher |
| Gross margin as of 2026-07-25 | +0.0% | n/a | |
| Operating margin as of 2026-07-25 | -500.0% | -8108.3% | RLMD higher |
| ROE as of 2026-07-25 | -71.2% | -291.2% | RLMD higher |
| ROA as of 2026-07-25 | -64.5% | -243.1% | RLMD higher |
| Debt / equity as of 2026-07-25 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-25 | 0.50 | -1.34 | |
| 1-year return as of 2026-07-23 close | +678.7% | -46.5% | RLMD higher |
Fundamentals: Finnhub, as of 2026-07-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.